Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around...
-
Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Selective Estrogen Receptor Modulators Market by Product Type, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast to...
-
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published...
-
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of...
-
4D Path QPORTM platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate
-
Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab...
-
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with...
-
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2025" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market is...
-
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology...
-
New York, USA, April 30, 2025 (GLOBE NEWSWIRE) -- Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight In recent years, the...